Biotech | January 18, 2022
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
The stability is led by healthy demand in the domestic and emerging markets
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
This surpasses the number of approvals supported in 2020
Subscribe To Our Newsletter & Stay Updated
